BB 3103
Latest Information Update: 14 Aug 2001
Price :
$50 *
At a glance
- Originator British Biotech
- Class Antineoplastics
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Aug 2001 Discontinued-Preclinical for Cancer in United Kingdom (Unknown route)
- 10 Nov 1999 New profile
- 10 Nov 1999 Preclinical development for Cancer in United Kingdom (Unknown route)